RESUMEN
An important step in adoptive immunotherapy in general and specifically with respect to cancer treatment is the initiation of an inflammatory T cell response at the tumor site. Here we suggest a new concept for a controlled inflammatory response in which the intrinsic cytotoxic properties of T cells are upgraded with the properties of nanoparticles transfected into the T cells during the ex vivo expansion process. We report in vitro upgrading of human T cells using PEGylated boron carbide nanoparticles functionalised with a translocation peptide aimed at Boron Neutron Capture Therapy (BNCT). A key finding is that the metabolism of such upgraded human T cells were not affected by a payload of 0.13 pg boron per cell and that the nanoparticles were retained in the cell population after several cell divisions. This is vital for transporting nanoparticles by T cells to the tumor site.
Asunto(s)
Portadores de Fármacos , Inmunoterapia Adoptiva , Nanopartículas/uso terapéutico , Linfocitos T/inmunología , Secuencia de Aminoácidos , Citometría de Flujo , Humanos , Datos de Secuencia MolecularRESUMEN
In this paper we present surface modification strategies of boron carbide nanoparticles, which allow for bioconjugation of the transacting transcriptional activator (TAT) peptide and fluorescent dyes. Coated nanoparticles can be translocated into murine EL4 thymoma cells and B16 F10 malignant melanoma cells in amounts as high as 0.3 wt. % and 1 wt. %, respectively. Neutron irradiation of a test system consisting of untreated B16 cells mixed with B16 cells loaded with boron carbide nanoparticles were found to inhibit the proliferative capacity of untreated cells, showing that cells loaded with boron-containing nanoparticles can hinder the growth of neighboring cells upon neutron irradiation. This could provide the first step toward a T cell-guided boron neutron capture therapy.
Asunto(s)
Compuestos de Boro , Terapia por Captura de Neutrón de Boro , Nanoestructuras/química , Linfocitos T/metabolismo , Animales , Compuestos de Boro/química , Compuestos de Boro/metabolismo , Línea Celular Tumoral/efectos de la radiación , Proliferación Celular , Melanoma , Ratones , Estructura Molecular , Tamaño de la PartículaRESUMEN
Boron carbide nanoparticles are proposed as a system for T cell-guided boron neutron capture therapy. Nanoparticles were produced by ball milling in various atmospheres of commercially available boron carbide. The physical and chemical properties of the particles were investigated using transmission electron microscopy, photon correlation spectroscopy, X-ray photoelectron spectroscopy, X-ray diffraction, vibrational spectroscopy, gel electrophoresis and chemical assays and reveal profound changes in surface chemistry and structural characteristics. In vitro thermal neutron irradiation of B16 melanoma cells incubated with sub-100 nm nanoparticles (381.5 microg/g (10)B) induces complete cell death. The nanoparticles alone induce no toxicity.
Asunto(s)
Compuestos de Boro/síntesis química , Compuestos de Boro/uso terapéutico , Terapia por Captura de Neutrón de Boro/métodos , Melanoma/patología , Melanoma/radioterapia , Nanoestructuras/química , Radioinmunoterapia/métodos , Linfocitos T/trasplante , Animales , Línea Celular Tumoral , Proliferación Celular/efectos de la radiación , Marcaje Isotópico , Ratones , Tamaño de la Partícula , Radioisótopos/química , Radioisótopos/uso terapéutico , Radiofármacos/síntesis química , Resultado del TratamientoRESUMEN
We have demonstrated previously that gene transfer of the mature human interleukin-1beta (IL-1beta) gene, fused to a signal sequence (ss), into mouse B16 melanoma cells results in an inhibition of their growth in vivo compared with control B16 cells. We here extend these results to show that intraperitoneal vaccinations with irradiated IL-1beta-secreting cells result in protection against subsequent subcutaneous challenge with wild-type (wt) B16 tumor cells in syngeneic C57BL/6 mice. This protection appears to be long-lasting, because rechallenge of cured mice 4 months after the first challenge also demonstrated resistance. In addition, we demonstrate that mice with established wt tumors subjected to therapeutic vaccinations with irradiated B16/ssIL-1beta cells starting 3 days after challenge isografting have a significantly inhibited tumor growth and 25-40% survival at the challenge doses given. In vitro coculture of spleen cells from B16/ssIL-1beta vaccinated animals and wt B16 cells induced an enhanced proliferative response, which correlated with elevated production of IL-2 and interferon-gamma. A significantly enhanced cytolytic activity against B16 wt target tumor cells was observed when spleen cells from B16/ssIL-1beta vaccinated mice were used as effector cells compared with spleen cells from control vaccinated mice. In vitro depletion experiments using anti-asialo GM1 revealed a prominent role for natural killer cells as effector cells. The data suggest that local IL-1beta secretion during the vaccination phase can provoke or augment protective immune responses to B16 melanoma cells, which are otherwise not recorded in mice bearing B16 tumors.
Asunto(s)
Vacunas contra el Cáncer/uso terapéutico , Terapia Genética/métodos , Interleucina-1/genética , Melanoma Experimental/terapia , Retroviridae/genética , Animales , Antígenos CD4/metabolismo , Supervivencia Celular/efectos de los fármacos , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Humanos , Inmunidad Celular , Interleucina-1/biosíntesis , Células Asesinas Naturales/inmunología , Melanoma Experimental/inmunología , Ratones , Ratones Endogámicos C57BL , Trasplante de Neoplasias , Cavidad Peritoneal , Receptores de Interleucina-2/metabolismo , Bazo/inmunología , Linfocitos T/fisiología , Linfocitos T Citotóxicos/fisiología , Células TH1/inmunología , Factores de Tiempo , Transducción Genética , Células Tumorales Cultivadas/efectos de la radiaciónAsunto(s)
Interleucina-1/inmunología , Neoplasias/inmunología , Animales , Anticarcinógenos/inmunología , Supervivencia Celular/efectos de los fármacos , Técnicas de Transferencia de Gen , Terapia Genética , Humanos , Interleucina-1/genética , Interleucina-1/uso terapéutico , Neoplasias/terapia , Isoformas de Proteínas/genética , Isoformas de Proteínas/inmunología , Isoformas de Proteínas/uso terapéuticoRESUMEN
To evaluate the biological effects of over-expression of interleukin-1beta (IL-1beta) on the immune system we have generated transgenic mice, expressing the IL-1beta gene fused to a heterologous signal sequence under the control of the mouse immunoglobulin enhancer (Emu). A prominent hyperplasia and a disturbed microarchitecture of lymphoid tissues were observed in the transgenic mice. The CD4+ T cells in the hyperplastic lymphoid organs seemed to invade the majority of the lymphoid organs including B-cell restricted areas. Analysis of lymph node cells revealed an increased frequency of CD4+ CD44high CD62L- T cells and local secretion of IL-2 and IL-4, compatible with an elevated number of activated T cells. Furthermore, significant levels of human IL-1beta in sera and high concentrations of serum immunoglobulin G (IgG) were observed in the transgenic mice. The data suggest a role for IL-1beta in controlling lymphoid microarchitecture and, when over-expressed, breaking the threshold in T-helper-B-cell interaction.
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Interleucina-1/metabolismo , Ganglios Linfáticos/inmunología , Activación de Linfocitos , Ratones Transgénicos/inmunología , Animales , Antígenos de Diferenciación de Linfocitos T/análisis , Linfocitos T CD4-Positivos/patología , Ensayo de Inmunoadsorción Enzimática/métodos , Citometría de Flujo , Humanos , Receptores de Hialuranos/análisis , Hiperplasia , Inmunoglobulina A/sangre , Inmunoglobulina G/sangre , Inmunohistoquímica , Inmunofenotipificación , Interleucina-1/sangre , Interleucina-2/análisis , Interleucina-4/análisis , Selectina L/análisis , Ganglios Linfáticos/patología , Ratones , Ratones Endogámicos C57BL , Isoformas de Proteínas/análisis , Isoformas de Proteínas/metabolismo , Bazo/inmunología , Bazo/patologíaRESUMEN
Interleukin(IL)-1 differs from most other cytokines in its lack of a signal sequence. This results in intracellular retention of the immature proform. The release of IL-1 has been shown to be restricted predominantly to activated monocytes and macrophages and to be associated with apoptosis of the producer cell. These features have limited the investigation of IL-1 in early immune responses. In order to study the biological effects of local IL-1 beta release during an antitumour immune response, we used B16 mouse melanoma cells transduced with mature human IL-1 beta cDNA constructs. To obtain a released form of human IL-1 beta (ssIL-1 beta), the signal sequence from the related IL-1 receptor antagonist was ligated to the cDNA that encoded the mature form of IL-1 beta. When cells of the poorly immunogenic B16 melanoma cell line were transduced with IL-1 beta by retroviral infection, high levels of the protein were detected intracellularly, whereas cells transduced with IL-1 beta containing the signal sequence secreted most of their protein. The in vitro growth of the melanoma cells was unaffected by the IL-1 beta or ssIL-1 beta gene transfer. In contrast, the in vivo subcutaneous tumour growth of the ssIL-1 beta-transduced B16 cells in syngeneic C57BL/6 mice was significantly reduced compared with the IL-1 beta- and the mock-transduced controls. Immunohistochemical analysis revealed the infiltration of macrophages to be strong in B16/ssIL-1 beta, moderate in B16/IL-1 beta and minimal in control tumours. Furthermore, a moderate infiltration of CD4+ cells and of scattered dendritic cells was detected in B16/ssIL-1 beta tumours whereas very few or no CD4+ cells and dendritic cells were seen in the B16/IL-1 beta or control tumours. Following in vivo growth, all the tumours upregulated ICAM-1 on their cell surfaces. However, the percentage of ICAM-1-expressing cells was two- to four-fold higher in B16/ssIL-1 beta tumours compared to the control. The data suggest that IL-1 beta acts in vivo, either directly or indirectly, as a chemotactic factor for monocytes, T helper cells and dendritic cells. This supports IL-1 beta having a regulatory effect on tumour growth when locally released in the tumour area.
Asunto(s)
Células Dendríticas/inmunología , Interleucina-1/metabolismo , Macrófagos/inmunología , Melanoma Experimental/inmunología , Subgrupos de Linfocitos T/inmunología , Animales , Citometría de Flujo , Ingeniería Genética , Humanos , Inmunohistoquímica , Interleucina-1/genética , Melanoma Experimental/genética , Melanoma Experimental/patología , Ratones , Ratones Endogámicos C57BL , Señales de Clasificación de Proteína/genética , Análisis de SupervivenciaRESUMEN
Interleukin (IL)-1 differs from most other cytokines by the lack of a signal sequence, which results in the retention of the immature proform intracellularly (i.c.). Several cell types have the capacity to produce IL-1, but release has been shown to be restricted predominantly to monocytes/macrophages and associated with apoptosis of the producer cell. These features have limited the studies on IL-1 in early T cell-APC interactions. To develop a model for studying the biological effects of IL-1 beta release during long-lasting immune responses, we have established cells transfected with IL-1 beta cDNA constructs. To construct a hybrid gene for IL-1 beta release, the signal sequence from the related IL-1 receptor antagonist was fused to the gene encoding the 17-kDa mature form of IL-1 beta. A murine fibroblast cell line was transduced with retroviral technique and analyzed for the expression of human IL-1 beta, with or without a signal sequence (ssIL-1 beta and IL-1 beta, respectively). The fibroblasts transduced with either IL-1 beta or ssIL-1 beta expressed similar levels of human IL-1 beta mRNA. High levels of IL-1 bioactivity were recorded in freeze-thaw extracts from cells expressing the IL-1 beta protein i.c., and in supernatants of ssIL-1 beta-transduced cells, which indicates that the initial formation of a proform of IL-1 beta is not required for correct folding of the protein. Treatment of ssIL-1 beta-transduced cells with Brefeldin A (BFA), an inhibitor of protein transport in the endoplasmatic reticulum, induced accumulation of the protein i.c. BFA treatment did not affect IL-1 beta-transduced cells, while lipopolysaccharide-activated human monocytes increased the secretion of IL-1 beta. Cytoplasmic staining of single cells demonstrated that expression of the ssIL-1 beta gene directed the protein to a perinuclear Golgi-like compartment, whereas cells transduced with IL-1 beta cDNA showed a diffuse cytoplasmic distribution pattern. Secretion of IL-1 beta from human monocytes was under certain conditions accompanied by cell death. In contrast, in the fibroblast cell line transduced to secrete IL-1 beta, no accompanying cell death could be detected. Gene targeting of IL-1 to the secretory or cytoplasmic pathway may be useful for elucidating the role of IL-1 in T cell-APC interactions, avoiding cell death of the producer cells.
Asunto(s)
Citoplasma/inmunología , Citoplasma/metabolismo , Espacio Extracelular/metabolismo , Interleucina-1/genética , Interleucina-1/metabolismo , Precursores de Proteínas/genética , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Células 3T3 , Animales , Secuencia de Bases , Brefeldino A , Muerte Celular/inmunología , Ciclopentanos/farmacología , Vectores Genéticos/química , Vectores Genéticos/inmunología , Glicosilación , Ratones , Datos de Secuencia Molecular , Peso Molecular , Precursores de Proteínas/farmacología , Inhibidores de la Síntesis de la Proteína/farmacología , ARN Mensajero/biosíntesis , Retroviridae/genética , Coloración y Etiquetado , TransfecciónRESUMEN
The A6H mAb raised primarily against human renal cell carcinoma (RCC) has previously been shown to bind strongly to RCC, to some degree to colon carcinoma but only marginally to a variety of normal tissues. Immunohistochemical analysis or RCC tissues containing tumor-infiltrating lymphocytes revealed that A6H stained both tumor cells and lymphocytes. FACS analysis of human peripheral blood cells demonstrated that A6H stained both tumor cells and lymphocytes. FACS analysis of human peripheral blood cells demonstrated that A6H mAb stained 85-90% of both CD4+ and CD8+ T cells, but not granulocytes, monocytes, NK cells or B cells. Furthermore, 85-90% of naive and memory T helper cells were stained with A6H suggesting that the A6H mAb defines unique subsets within these T cell populations. Dual staining showed that A6H mAb bind to an antigen that is clearly distinct from other cell surface molecules on T cells, including CD28, CD29, CD26, CD44 and ICAM-2. A6H mAb binding induced a second signal in anti-CD3 mAb activated T cells, resulting in cell proliferation, IL-2 receptor expression and vigorous production of IFN-gamma and TNF, and production of minor amounts of IL-2. Immunoprecipitation with A6H mAb indicated a molecular weight of 120-140 kDa on both T cells and RCC. We suggest that the A6H mAb defines a unique T cell surface antigen which is involved in signal transduction and is expressed on subsets of human T cells. The co-expression of A6H on T cells and tumor cells suggests a possible function related to common properties of these cells.